https://www.selleckchem.com/pr....oducts/durvalumab.ht
Real-world re-treatment intervals for botulinum toxins vary, but most subjects receive treatment less frequently than the manufacturer-recommended minimum intervals. In subjects receiving treatment with AbobotulinumtoxinA (ABO) less frequently, high levels of satisfaction and psychosocial improvements in well-being, self-confidence, and quality of life are observed. To evaluate subject satisfaction with a twice yearly re-treatment schedule. This open-label, multicenter, interventional study evaluated subject satisfaction following in